Two health advocacy groups have written to the Indian government asking it to revoke patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus patients around the world, particularly in poorer nations. To expand its access, Gilead said this week it had signed non-exclusive licensing pacts with five generic drug makers based in India and Pakistan, allowing them to make and sell remdesivir for 127 countries. Gilead filed a patent application for remdesivir in India in 2015, which was granted on February 18, 2020. The drug is currently in the clinical trial stage and has not yet received marketing approval. But health access groups say the pacts mean cheaper forms of the drug may not become available in nations seen as non-profitable to the five drugmakers. Drug patents in India are an important issue as many countries depend on generic drugmakers to make and sell cheaper versions of critical drugs to them. Remdesivir is the only drug approved to treat COVID-19 patients after promising early trial results prompted U.S. regulators to grant emergency use authorization on May 2. (with inputs from Reuters)

Like our work? Click here to support The Wire: https://thewire.in/support

The founding premise of The Wire is this: if good journalism is to survive and thrive, it can only do so by being both editorially and financially independent. This means relying principally on contributions from readers and concerned citizens who have no interest other than to sustain a space for quality journalism. As a publication, The Wire will be firmly committed to the public interest and democratic values.
We publish in four different languages!
For English, visit www.thewire.in
for Hindi: http://thewirehindi.com/
for Urdu: http://thewireurdu.com
for Marathi: https://marathi.thewire.in
If you are a young writer or a creator, you can submit articles, essays, photos, poetry – anything that’s straight out of your imagination – to LiveWire, The Wire’s portal for the young, by the young. https://livewire.thewire.in/
You can also follow The Wire’s social media platforms and engage with us.
Facebook
https://www.facebook.com/TheWire/
https://www.facebook.com/TheWireHindi/
https://www.facebook.com/TheWireUrdu/
https://www.facebook.com/TheWireMarathi/
Twitter
https://twitter.com/thewire_in
https://twitter.com/thewirehindi
https://twitter.com/TheWireUrdu
https://twitter.com/TheWireMarathi
https://twitter.com/livewire
Instagram
https://www.instagram.com/thewirein/
https://www.instagram.com/livewirein/
Don’t forget to hit the subscribe button to never miss a video from The Wire!